Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Assets Average (2016 - 2025)

Guided Therapeutics' Assets Average history spans 14 years, with the latest figure at $921500.0 for Q3 2025.

  • For Q3 2025, Assets Average fell 26.28% year-over-year to $921500.0; the TTM value through Sep 2025 reached $921500.0, down 26.28%, while the annual FY2024 figure was $1.5 million, 39.48% down from the prior year.
  • Assets Average for Q3 2025 was $921500.0 at Guided Therapeutics, down from $953500.0 in the prior quarter.
  • Across five years, Assets Average topped out at $3.6 million in Q4 2022 and bottomed at $921500.0 in Q3 2025.
  • The 5-year median for Assets Average is $1.9 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Assets Average soared 239.13% in 2021 before it plummeted 51.0% in 2023.
  • A 5-year view of Assets Average shows it stood at $1.9 million in 2021, then skyrocketed by 91.25% to $3.6 million in 2022, then crashed by 51.0% to $1.8 million in 2023, then decreased by 25.92% to $1.3 million in 2024, then decreased by 29.84% to $921500.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Assets Average are $921500.0 (Q3 2025), $953500.0 (Q2 2025), and $1.2 million (Q1 2025).